- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2023 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Latest Conference Articles
Educated Patient® Prostate Cancer Summit Genetics & Genomics Panel: May 21, 2022
June 13th 2022, 1:00pm
Educated Patient® Prostate Cancer Summit: May 21, 2022
Watch Dr. Veda N. Giri, Dr. Umang Swami and Sue Friedman answer questions about genetics and genomics during the CURE Educated Patient Prostate Cancer Summit.
Educated Patient® Prostate Cancer Summit Genomics Presentation: May 21, 2022
June 12th 2022, 2:00pm
Educated Patient® Prostate Cancer Summit: May 21, 2022
Watch Dr. Umang Swami, from Huntsman Cancer Institute, discuss genomic changes and PARP inhibitors, during the CURE Educated Patient Prostate Cancer Summit.
Educated Patient® Prostate Cancer Summit Genetic Testing Presentation: May 21, 2022
June 11th 2022, 2:00pm
Educated Patient® Prostate Cancer Summit: May 21, 2022
Watch Dr. Veda N. Giri, from Sidney Kimmel Cancer Center at Thomas Jefferson University, discuss genetic testing and who should get it, during the CURE Educated Patient Prostate Cancer Summit.
_iStock_000004521955Medium.jpg?w=350&fit=crop&auto=format)
Brukinsa Continues to Outperform Imbruvica for MYD88-Mutant Waldenström Macroglobulinemia
June 10th 2022, 9:00pm
Brukinsa, which was approved in September 2021, resulted in better ouctomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.
Addition of Stem Cell Transplant Boosts Outcomes for Common Myeloma Regimen
June 10th 2022, 7:00pm
Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant.
Educated Patient® Prostate Cancer Summit Treatment in Localized Disease Panel: May 21, 2022
June 10th 2022, 1:00pm
Educated Patient® Prostate Cancer Summit: May 21, 2022
Watch Dr. Ganesh Raj, Dr. Andrew Z. Wang, and Bruce Williams, discuss treatment for localized disease, during the CURE Educated Patient Prostate Cancer Summit.
Pre- and Post-Surgical Jakafi Plus Chemo Shows Potential in Advanced Ovarian Cancer
June 9th 2022, 7:00pm
The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.
Keytruda Demonstrates Significant Improvement for Some Patients with Melanoma
June 9th 2022, 3:00pm
Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo.
Educated Patient® Prostate Cancer Summit Approaches to Radiation Presentation: May 21, 2022
June 9th 2022, 1:00pm
Educated Patient® Prostate Cancer Summit: May 21, 2022
Watch Dr. Andrew Z. Wang, from UT Southwestern Medical Center, discuss approaches to radiation for local disease, during the CURE Educated Patient Prostate Cancer Summit.
Durable Responses Continue with Keytruda Plus Chemoradiation in Previously Untreated Non-Small Cell Lung Cancer
June 8th 2022, 9:00pm
After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.
Jemperli Eliminated All Signs of Rectal Cancer in Small Clinical Trial, Warranting Further Research
June 8th 2022, 7:00pm
One-hundred percent of patients with stage 2/3 mismatch repair-deficient rectal cancer had their disease disappear after treatment with Jermperli, though more research and longer follow-up is needed.
Exkivity Delivers Minimal Benefit to Patients with Non-Small Cell Lung Cancer and Brain Metastases
June 8th 2022, 3:00pm
Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.
Educated Patient® Prostate Cancer Summit Overview of Surgery Presentation: May 21, 2022
June 8th 2022, 1:00pm
Educated Patient® Prostate Cancer Summit: May 21, 2022
Watch Dr. Ganesh V. Raj, from UT Southwestern Medical Center, discuss surgery for localized disease, during the CURE Educated Patient Prostate Cancer Summit.
Ifosfamide Induces ‘Subtle’ Survival Improvement Over Hycamtin-Cyclophosphamide Combo in Ewing Sarcoma
June 7th 2022, 9:00pm
The use of the chemotherapy ifosfamide was associated with small improvements in survival outcomes in a group of patients with relapsed/refractory Ewing sarcoma, a rare type of bone or soft tissue cancer.
Enhertu Fulfills ‘Big Unmet Need’ for Patients with HER2-Low Metastatic Breast Cancer
June 7th 2022, 3:00pm
The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.
Addition of Tiragolumab to Tecentriq-Chemo Combo Fails to Boost Outcomes in Small Cell Lung Cancer
June 6th 2022, 9:00pm
Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.
Keytruda-Cyramza Combo Bests Standard-of-Care Therapies in Previously Treated Non-Small Cell Lung Cancer
June 6th 2022, 7:00pm
Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.
Early Study Findings Show Novel Drug Elicits Promising Results in Metastatic Breast Cancers
June 6th 2022, 3:00pm
At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.
SOT101 With or Without Keytruda Shows Promise, Safety in Treating Advanced Solid Tumors
June 6th 2022, 1:00pm
The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.
Calquence-Based Regimens Continue to Elicit Better Results Than Gazyva Plus Chemotherapy in Untreated Chronic Lymphocytic Leukemia
June 5th 2022, 10:00pm
Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.
Trodelvy Reduces Risk of Disease Progression in Certain Patients With Metastatic Breast Cancer
June 5th 2022, 5:15pm
Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Adcetris Plus Chemo ‘Potentially Cured’ Some Patients With Hodgkin Lymphoma
June 5th 2022, 1:00pm
Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.
Tibsovo Plus Vidaza Is Beneficial for Patients With IDH1-Mutant Acute Myeloid Leukemia
June 4th 2022, 11:50pm
Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.
Cabometyx Failed to Improve Survival in Advanced Bladder Cancer
June 4th 2022, 10:00pm
While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.
New Drug May Mitigate Incidence, Severity of Chemotherapy-Related Oral Mucositis in Patients With Head and Neck Cancer
June 4th 2022, 7:00pm
Avasopasem manganese is the first drug that has been shown to reduce the incidence and severity of chemotherapy-related oral mucositis in patients with head and neck cancer, research showed.
Treatment With Vonjo May Elicit Fewer Side Effects Than Other Available Therapies in Myelofibrosis, a Rare Type of Blood Cancer
June 4th 2022, 3:00pm
Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.
Adagrasib Shows Promise in Difficult-to-Treat Lung Cancer Subset
June 4th 2022, 1:00pm
Adagrasib demonstrated an 80% disease control rate among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.
Hispanic Children With Neuroblastoma Have Poorer Trial Outcomes: Describing Disparities Is ‘Simply Not Enough’
June 1st 2022, 3:00pm
Research showed that Hispanic children with neuroblastoma who are participating on clinical trials tended to have worse survival outcomes than others.
Educated Patient® MPN Summit Disease Approaches Panel: May 7, 2022
May 24th 2022, 1:00pm
Educated Patient® MPN Summit: May 7, 2022
Watch Dr. Jamile Shammo and Dr. Srdan Vestovsek answer questions about disease approaches during the CURE Educated Patient MPN Summit.
Educated Patient® MPN Summit Novel Agents & Clinical Trials in Myelofibrosis Presentation: May 7, 2022
May 23rd 2022, 1:00pm
Educated Patient® MPN Summit: May 7, 2022
Watch Dr. Srdan Vestovsek, from The University of Texas MD Anderson Cancer Center, discuss novel agents and clinical trials in myelofibrosis, during the CURE Educated Patient MPN Summit.